Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICS-V: saroglitazar magnesium in primary biliary cholangitis with cirrhosis
2025-524067-20-00Phase 4Authorised
- Sponsor
- Zydus Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 4, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Saroglitazar magnesium with Placebo (2 arms). Primary endpoint: Time to first clinical outcome event composite. Planned start Oct 2026; status: authorised.
02
Drugs
saroglitazar magnesium
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2025-524067-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524067-20-00.